Vanda Pharmaceuticals reported $-8306000 in EBITDA for its fiscal quarter ending in December of 2024.


Ebitda Change Date
Acadia Pharmaceuticals USD 35.31M 13.07M Jun/2025
Agios Pharmaceuticals USD -125797000 20.45M Jun/2025
Alnylam Pharmaceuticals USD 18.83M 13.65M Jun/2025
Arrowhead Research USD -159327000 556.67M Jun/2025
AstraZeneca USD 4.96B 127M Jun/2025
Bristol-Myers Squibb USD 3.27B 1.63B Jun/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
Halozyme Therapeutics USD 225.5M 63.51M Jun/2025
Insmed USD -297127000 71.11M Jun/2025
J&J USD 7.88B 1.76B Mar/2025
Ligand Pharmaceuticals USD -40543000 50.88M Mar/2025
Merck USD 7.74B 625M Mar/2025
Moderna USD -760000000 164M Jun/2025
Novartis USD 6.08B 739M Jun/2025
Pfizer USD 5.32B 889M Jun/2025
PTC Therapeutics USD 971.14M 970.07M Mar/2025
Sanofi EUR 1.89B 971M Jun/2025
Takeda JPY 366.2B 238.06B Jun/2025
Teva Pharmaceutical Industries USD 1.23B 124M Jun/2025
Ultragenyx Pharmaceutical USD -91344000 35.09M Jun/2025
Veracyte USD 35.78M 29.25M Jun/2025